Pipeline

BP1200

  1. BP1200, a novel antibody targeting CD73, improves the tumor microenvironment and activates anti-tumor immunity.

CD73 is responsible for adenosine generation in tumors, which causes T cell exhaustion and suppression and decreases antitumor immunoreactivity

CD73 is highly expressed in many tumors, leading to poor prognosis.

image

BP1200 is a humanized antibody that is a potentially best-in-class immune checkpoint inhibitor targeting CD73 expressed on tumor and immune cells. CD73 is a cell surface enzyme that is expressed on tumor cells and converts extracellular adenosine monophosphate (AMP) into immunosuppressive adenosine. Adenosine production inhibits T cell and NK cell cytotoxicity, cytokine production, and proliferation as well as suppression of antigen presenting cells and macrophage M2 polarization, which enables tumor growth and disease progression. BP1200 ameliorates the suppressive tumor microenvironment by attenuating adenosine production and reestablishes a broad anti-tumor response mediated by tumor infiltrating T cells which includes enhancement of proliferation, cytokine production, and cytotoxicity of T cells. BP1200 in combination with other complementary immune pathways such as PD-1/PD-L1, is a key strategy to enhance the anti-tumor cytotoxic potential of immunotherapy.

A novel therapeutic antibody against CD73 that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy. AACR 2022
VIEW POSTER

A novel therapeutic antibody against CD73 that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy.  ESMO 2021
VIEW POSTER

close